Sulopenem (oral)
Uncomplicated Urinary Tract Infection (uUTI) in women with quinolone-non-susceptible pathogens
Key Facts
Indication
Uncomplicated Urinary Tract Infection (uUTI) in women with quinolone-non-susceptible pathogens
Phase
Phase 3
Status
Clinical Hold / NDA Resubmission Under Evaluation
Company
About Iterum Therapeutics
Iterum Therapeutics is dedicated to addressing the critical public health crisis of antimicrobial resistance by developing next-generation antibiotics. Its primary candidate, sulopenem, is designed to treat resistant urinary tract infections (UTIs) and intra-abdominal infections where current oral options are failing. Despite facing significant setbacks, including a Complete Response Letter from the FDA for its NDA, the company continues to seek pathways to bring sulopenem to patients. Iterum operates as a lean, publicly traded entity (NASDAQ: ITRM) strategically headquartered in Ireland.
View full company profile